Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients

Published:2017-10-08 Issue:3 Volume:179 Page:410-420
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Pfreundschuh Michael¹^ORCID,Murawski Niels¹,Zeynalova Samira²,Ziepert Marita²,Loeffler M.²,Hänel Matthias³,Dierlamm Judith⁴,Keller Ulrich⁵^ORCID,Dreyling Martin⁶,Truemper Lorenz⁷,Frickhofen Norbert⁸,Hünerlitürkoglu Ali-Nuri⁹,Schmitz Norbert¹⁰,Pöschel Viola¹,Rixecker Tanja¹,Berdel Christian¹⁰,Rübe Christian¹¹,Held Gerhard¹,Zwick Carsten¹

Affiliation:

1. Klinik für Innere Medizin I; Universitätsklinikum des Saarlandes; Homburg Germany

2. IMISE; Leipzig University; Leipzig Germany

3. Städtisches Klinikum Chemnitz; Chemnitz Germany

4. Universitätsklinikum Hamburg-Eppendorf; Hamburg Germany

5. Medizinische Klinik III; Klinikum rechts der Isar; Technische Universität; Munich Germany

6. Klinikum Großhadern; Munich Germany

7. Abteilung Hämatologie; Universitätsmedizin Göttingen; Göttingen Germany

8. Dr. Horst-Schmidt-Kliniken; Wiesbaden Germany

9. Lukas-Krankenhaus; Neuss Germany

10. Asklepios Klinik St. Georg; Hamburg Germany

11. Klinik für Strahlentherapie; Universitätsklinikum des Saarlandes; Homburg Germany

Funder

Deutsche Krebshilfe

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14860/fullpdf

Reference21 articles.

1. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease;Brosteanu;Annals of Hematology,2004

2. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology,1999

3. Rituximab-dose dense chemotherapy ± high-dose chemotherapy plus autotransplant in poor risk DLBCL: final results of the DLCL04 phase III multicenter randomized study;Chiappella;Lancet Oncology,2017

4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;The New England Journal of Medicine,2002

5. Phramcokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINE): stage 1 analysis of a radnomised phase 3 study;Davies;Lancet Oncology,2014

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials—a LYSA and GLA/ DSHNHL collaboration;Leukemia;2024-08-16

2. Sex as a Biological Variable in Early-Phase Oncology Clinical Trials: Enhancing the Path to Personalised Medicine;Heliyon;2024-06

3. Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy;International Journal of Molecular Sciences;2024-03-01

4. Geschlechterperspektiven in der medizinischen Forschung und Versorgung;Edition Fachdidaktiken;2024

5. Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma;Journal of Clinical Oncology;2023-10-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3